Portalak syrup for oral administration 66.7%, 500ml

1. constipation (including chronic)

2. the need to soften the stool for medical purposes (with hemorrhoids, the need for surgery on the colon and / or anus, pain after removal of hemorrhoids, postoperative period)

3. intestinal dysbiosis

4. hepatic encephalopathy

5. hepatic precoma and coma (treatment and prevention)

6. hyperammonemia

7. enteritis caused by salmonella, shigella, salmonella carriers;

8. putrid dyspepsia syndrome (in young children as a result of acute food poisoning).

Inside, in the morning during or after a meal, once or divided into 2 doses, washed down with water or other liquid.

The dose of the drug is selected individually.

The drug is best taken in the morning during or after meals, once or divided into two doses. The drug can be taken with water or other liquid. The patient can select and change the dose and time of taking the drug as needed. The laxative effect of the drug develops during the first two days of administration.
The duration of treatment for constipation is from 4 weeks to 3-4 months.

In the treatment of hepatic (portal) encephalopathy, hepatic coma and precoma:
30-50 ml of syrup (2-3 tablespoons) three times a day.
In the initial phase of treatment, doses of 30-45 ml of syrup may be prescribed every 1-2 hours to achieve a quick effect (first bowel movement). Then they switch to a maintenance dose, selecting it individually, in order to get soft stools 2-3 times a day.

In the treatment of dysbiosis and to normalize the intestinal microflora:
The drug is prescribed during or after meals, 2 to 4 times a day.

The duration of treatment is 10-14 days, repeated courses are prescribed at weekly intervals.

100 ml of syrup contains 66.7 g of lactulose concentrate.
Excipients: purified water.

• Hypersensitivity to lactulose or other components of the drug,

• galactosemia,

• intestinal obstruction,

• rectal bleeding (not caused by hemorrhoids)

• colo-, ileostomy,

• suspicion of appendicitis.

Trade name of the drug: PortalacЃ

International non-proprietary name:

Lactulose

Dosage form:

Syrup

Composition:

100 ml of syrup contains 66.7 g of lactulose concentrate.
Excipients: purified water.

Description
Transparent viscous liquid from colorless to brownish-yellow color.

Pharmacotherapeutic group:

laxative.

ATX CODE: A06AD11

Pharmacological properties:

It has a hyperosmotic, laxative effect, stimulates intestinal motility, improves the absorption of phosphates and Ca2 + salts, and promotes the excretion of ammonium ions. Under the influence of lactulose, Lactobacillus acidophilus, Lactobacillus bifidus multiply in the intestine, which in turn leads to a decrease in pH in the lumen of the large intestine and the activation of its peristalsis. Along with this, the volume increases and the feces soften. The drug has a laxative effect without directly affecting the mucous membrane and smooth muscles of the large intestine.
Under the influence of lactulose, the formation of nitrogen-containing toxic substances in the proximal colon and their absorption into the systemic circulation decreases.
The concentration of ammonium ions in the blood decreases by 25-50%, reduces the severity of hepatic encephalopathy, improves mental state and normalizes the EEG.
The drug has the ability to inhibit the growth of Salmonella in the large intestine. The effect of the drug occurs within 24 - 48 hours after ingestion as the drug passes through the gastrointestinal tract.
Lactulose is practically not absorbed from the gastrointestinal tract (not more than 3% of the taken dose is absorbed), does not reduce the absorption of vitamins, does not cause addiction.

Indications for use:

1. constipation (including chronic)

2. the need to soften the stool for medical purposes (with hemorrhoids, the need for surgery on the colon and / or anus, pain after removal of hemorrhoids, postoperative period)

3. intestinal dysbiosis

4. hepatic encephalopathy

5. hepatic precoma and coma (treatment and prevention)

6. hyperammonemia

7. enteritis caused by salmonella, shigella, salmonella carriers;

8. putrid dyspepsia syndrome (in young children as a result of acute food poisoning).

Contraindications:

• Hypersensitivity to lactulose or other components of the drug,

• galactosemia,

• intestinal obstruction,

• rectal bleeding (not caused by hemorrhoids)

• colo-, ileostomy,

• suspicion of appendicitis.

Side effects:
Side effects are usually mild and reversible and are the result of exceeding the dose. Cramps, abdominal discomfort or pain, and diarrhea can be relieved by lowering the dose.
Flatulence appearing at the beginning of treatment, as a rule, disappears in 1-2 days.
There have been cases of skin reactions (rash).
With long-term therapy with high doses of lactulose in the treatment of hepatic encephalopathy, a violation of the water-electrolyte balance may develop, and, as a result, convulsions, nausea, headache, dizziness, arrhythmias, myalgia, increased fatigue, weakness.

Overdose:
Taking too high doses of the drug can cause diarrhea and imbalance in water and electrolyte balance.
Treatment: drug withdrawal.

Interaction with other medicinal products:

When using therapeutic doses of lactulose, there were no clinically significant interactions with other drugs, however, it is not recommended to take PORTALAC within two hours after taking another drug.
With the simultaneous administration of lactulose, it can inactivate drugs, for the release of which an unfavorable environment will be created in the large intestine (for example, drugs containing mesalazine).
Antibiotics (neomycin) and antacids reduce the effect.

Influence on the ability to drive vehicles and mechanisms
In the recommended doses, PORTALAC does not affect the ability to drive vehicles and mechanisms.

Special instructions and precautions:
If constipation persists within a few days of taking the drug, or if constipation recurs after stopping the drug, you should consult your doctor.
Due to the presence of small amounts of sugars in the preparation (15 ml of syrup contains up to 1.7 g of galactose and up to 1 g of lactose), precautions must be taken when prescribing the drug to patients with diabetes mellitus and lactose intolerance.
The drug is prescribed with caution to patients with gastrocardiac syndrome. In this case, treatment is started with low doses and increased gradually to avoid flatulence.
In the treatment of hepatic encephalopathy, especially in the initial phase of therapy, other laxatives should not be used. Increased bowel movement may lead to the erroneous conclusion that an adequate dose has been reached for the treatment of encephalopathy.
Lactulose can be used safely in pregnant and lactating women.

Release form:
Syrup 667 mg / ml.
250 ml and 500 ml of the drug in a high-density polyethylene bottle with a screw-on polypropylene cap, with a sealed polyethylene foam ring. One bottle, along with instructions for use, is placed in a cardboard box.

Storage conditions:
At a temperature not exceeding 25 ? —. Do not freeze due to possible crystallization of lactulose!
Keep out of the reach of children!

Expiration date:
3 years.
Do not use after the expiration date printed on the package.

Terms of dispensing from pharmacies:
Without prescription.